Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Other)

Overall Status

Recruiting

CT.gov ID

NCT04209686

Collaborator

Merck Sharp & Dohme LLC (Industry)

Enrollment

Location

Arm

Anticipated Duration (Months)

0.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety and clinical activity of paclitaxel plus olaparib and pembrolizumab in patients with previously treated advanced Gastric Cancer (GC).

Condition or Disease	Intervention/Treatment	Phase
Advanced Gastric Adenocarcinoma	Drug: Paclitaxel Drug: Olaparib Drug: Pembrolizumab	Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

36 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase 2 Study of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

Actual Study Start Date :

Jul 31, 2020

Anticipated Primary Completion Date :

Jul 1, 2024

Anticipated Study Completion Date :

Jul 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: All Participants All Participants will receive Paclitaxel, Olaparib and Pembrolizumab.	Drug: Paclitaxel Patients will receive treatment on Day 1 and 8 starting with cycle 2. Paclitaxel (80 mg) will be administered IV on days 1 and 8 starting with cycle 2 (every 21 days). Drug - Paclitaxel - 80mg IV Other Names: Taxol Drug: Olaparib Olaparib will be taken by mouth daily for 3 weeks (every 21 days). Drug - 100 mg or 300mg Other Names: Lynparza Drug: Pembrolizumab Patients will receive treatment every 21 days. Pembrolizumab (200 mg) will be administered IV on day 1 (every 21 days). Drug - 200mg IV Other Names: MK-3475; Keytruda

Arm

Intervention/Treatment

Experimental: All Participants

All Participants will receive Paclitaxel, Olaparib and Pembrolizumab.

Drug: Paclitaxel

Patients will receive treatment on Day 1 and 8 starting with cycle 2. Paclitaxel (80 mg) will be administered IV on days 1 and 8 starting with cycle 2 (every 21 days). Drug - Paclitaxel - 80mg IV

Other Names:

Taxol

Drug: Olaparib

Olaparib will be taken by mouth daily for 3 weeks (every 21 days). Drug - 100 mg or 300mg

Other Names:

Lynparza

Drug: Pembrolizumab

Patients will receive treatment every 21 days. Pembrolizumab (200 mg) will be administered IV on day 1 (every 21 days). Drug - 200mg IV

Other Names:

MK-3475; Keytruda

Outcome Measures

Primary Outcome Measures

Overall survival (OS) [4 years]
OS will be measured from the time of drug administration at Cycle 1, Day 1 until death due to any cause. All subjects who receive at least one dose of the 3-drug combination will be included. Subjects who discontinue treatment prior to Cycle 2 will not be included in the analysis. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which that patient was known to be alive. Estimation based on the Kaplan-Meier curve.

Secondary Outcome Measures

The number of patients experiencing study drug-related toxicities. [4 years]
Number of patients experiencing study drug-related adverse adverse events Grade 3 or higher as defined by CTCAE v5.0.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age ≥18 years.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Must have advanced gastric or gastroesophageal cancer.
Must have received and progressed on only one prior line of systemic therapy for advanced disease.
Must have the presence of measurable lesion.
Must agree to have a biopsy.
Life expectancy of greater than 3 months.
Patients must have adequate organ and marrow function defined by study - specified laboratory tests.
Woman of childbearing potential must have a negative pregnancy test.
Must use acceptable form of birth control while on study.
Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Require any antineoplastic therapy.
Require any other form of systemic or localized antineoplastic therapy.
Has received prior therapy with paclitaxel or PARP inhibitor. Previous paclitaxel may be allowed if no progression on or within 6 months of receiving this drug.
Hypersensitivity reaction to any paclitaxel, pembrolizumab or related compounds and/or to any of the components.
Allergy to dexamethasone, diphenhydramine and famotidine.
Is taking a moderate or strong CYP3A inhibitor.
Has uncontrolled intercurrent acute or chronic medical illness.
Has a known additional malignancy that is progressing and has required active treatment within the past 1 year.
Has received prior systemic anti-cancer therapy including investigational agents within 2 weeks prior to study treatment.
Has received prior radiotherapy within 2 weeks of start of study treatment.
Has received a live vaccine within 30 days prior to the first dose of study drug.
Is currently or has participated in another investigational study within 4 weeks prior to receiving study drug.
Has an active known or suspected autoimmune disease.
Has a diagnosis of immunodeficiency.
Prior tissue or organ allograft or allogeneic bone marrow transplantation.
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. .
Requires daily supplemental oxygen.
History of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
History of encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent.
Infection with HIV or hepatitis B or C at screening.
Has uncontrolled infection requiring systemic therapy..
Subjects unable to undergo venipuncture and/or tolerate venous access.
Has known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial.
Woman who are pregnant or breastfeeding.
A woman of childbearing potential (WOCBP) who has a positive urine pregnancy test within 72 hours prior to study drug initiation.